Tahir Hussain, an Indian American professor of Pharmacology at the University of Houston, has received a grant of USD 1.6 million from the National Institutes of Health (NIH) to examine a kidney cell that could prevent damage from inflammation caused by obesity.
The targeted cells express a protein called the angiotensin type 2 receptor (AT2R), which recently has been indicated to have anti-inflammatory and reno protective actions.
If activated, the AT2R will protect against chronic and acute kidney injury, Hussain said.
Hussain, originally from India and an alumnus of the Aligarh Muslim University, will study the impact of inflammation in kidneys with active AT2R as well as those with no AT2R.
"What I'm proposing in this grant is that certain cells in the kidney can protect the kidney itself," he said.
The expression of AT2R in the body is inherently low and hence, "weak", Hussain said, adding that "but because we know it has anti-inflammatory activity, we want to pump it up."
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
